Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Cash & Equivalents (2016 - 2025)

Abeona Therapeutics has reported Cash & Equivalents over the past 16 years, most recently at $78.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 231.03% year-over-year to $78.4 million; the TTM value through Dec 2025 reached $78.4 million, up 231.03%, while the annual FY2025 figure was $78.4 million, 231.03% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $78.4 million at Abeona Therapeutics, down from $82.9 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $163.9 million in Q2 2025 and troughed at $5.0 million in Q1 2023.
  • A 5-year average of $32.2 million and a median of $17.1 million in 2024 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 431.29% in 2021 and later plummeted 87.19% in 2022.
  • Year by year, Cash & Equivalents stood at $38.8 million in 2021, then plummeted by 62.52% to $14.6 million in 2022, then increased by 1.76% to $14.8 million in 2023, then surged by 59.98% to $23.7 million in 2024, then skyrocketed by 231.03% to $78.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for ABEO at $78.4 million in Q4 2025, $82.9 million in Q3 2025, and $163.9 million in Q2 2025.